Home / Business and Economy / MiniMed Files IPO, Eyes Nasdaq Debut
MiniMed Files IPO, Eyes Nasdaq Debut
20 Dec
Summary
- MiniMed filed for an initial public offering, seeking a Nasdaq listing.
- The diabetes management firm reported growing revenue and a shrinking net loss.
- Medtronic Plc plans to spin off the unit after nearly 25 years of ownership.
MiniMed Group Inc., poised for a significant market entry, has officially filed for an initial public offering (IPO) with the US Securities and Exchange Commission. The company, which operates as a distinct diabetes management entity following its separation from Medtronic Plc, disclosed encouraging financial trends including expanding revenue and a narrowing net loss. This filing signals MiniMed's intent to join the busy IPO calendar in early 2026, with aspirations for its shares to be listed on the Nasdaq Global Select Market.
The Northridge, California-based firm's IPO filing comes after a nearly 25-year tenure as part of Medtronic. MiniMed offers a comprehensive suite of diabetes care products, encompassing automated insulin pumps, continuous glucose monitors, and smart insulin pens, as detailed by CEO Que Dallara. The company projects approximately $2.7 billion in annual revenue for fiscal year 2025, bolstered by recent double-digit percentage growth. Medtronic, which announced its plan to separate the business in May 2025, will retain a significant ownership stake.
As part of the IPO process, MiniMed intends to allocate a portion of the proceeds towards repaying intercompany debt owed to its former parent, Medtronic. Leading the offering are major financial institutions including Goldman Sachs Group Inc., Bank of America Corp., Citigroup Inc., and Morgan Stanley. The planned distribution of Medtronic's shares to investors is expected to be largely tax-free, potentially structured as a spin-off, paving the way for MiniMed's independent future.
